Titre:
  • Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
Auteur:Ignatiadis, M; Litière, Saskia; Rothe, F; Riethdorf, Sabine; Proudhon, Charlotte; Fehm, T; Aalders, Kim K.C.; Forstbauer, Helmut; Fasching, P A; Brain, E; Vuylsteke, P; Guardiola, E; Lorenz, R; Pantel, K; Tryfonidis, Konstantinos; Janni, Wolfgang; Piccart, M; Sotiriou, Christos; Rack, B; Pierga, J-Y
Informations sur la publication:Annals of oncology, 29, 8, page (1777-1783)
Statut de publication:Publié, 2018-03-01
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Antineoplastic Agents, Immunological -- administration & dosage -- adverse effects
Breast -- pathology -- surgery
Breast Neoplasms -- blood -- mortality -- therapy
Cardiotoxicity -- epidemiology -- etiology
Chemotherapy, Adjuvant -- methods
Disease-Free Survival
Female
Humans
Mastectomy
Middle Aged
Neoplastic Cells, Circulating -- drug effects
Receptor, ErbB-2 -- antagonists & inhibitors -- metabolism
Trastuzumab -- administration & dosage -- adverse effects
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mdy211
info:pii/S0923-7534(19)34129-8
info:pmid/29893791